Research
Hormonal
Semaglutide (Wegovy) has demonstrated unprecedented efficacy in weight reduction, glycaemic control, and cardiovascular protection.
Semaglutide may be a highly effective treatment option for obesity and type 2 diabetes.
StrongSupportsmedium confidence
Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist, has demonstrated unprecedented efficacy in weight reduction, glycaemic control and cardiovascular protection in global clinical trials.
Why this rating
Based on global clinical trials.
Source
Injectable Semaglutide (Wegovy) in India: Promise, Pitfalls and the Way Forward
Mehul Kaliya et al. · NMO journal · 2025
reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →